BRAF and thyroid cancer: Vemurafenib, a selective BRAF inhibitor, could effectively be used in treating PTC with BRAFV600E mutation, suggesting that reduction in the activity of MAPK pathway by inhibiting BRAF is effective for treating thyroid cancer [40].